The CNS-penetrating taxane drug TPI 287 potentiates antiglioma activity of the AURKA inhibitor alisertib in vivo.
Müge SakBrian J WilliamsCory T ZumbarLandon TeerMustafa N G Al-KawaazAastha KakarAndrew J HeyMegan J WilsonLeslie M SchierJoseph ChenNorman L LehmanPublished in: Cancer chemotherapy and pharmacology (2023)
Results suggest that apoptosis is the dominant mechanism of potentiation of GBM growth inhibition by alisertib + TPI 287, in part through effects on Bcl-2 family proteins, providing a rationale for further laboratory testing of an AURKA inhibitor plus TPI 287 as a potential therapy against GBM.